| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
1228 Stock Overview
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide.
CANbridge Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$3.25 |
| 52 Week High | HK$9.99 |
| 52 Week Low | HK$3.25 |
| Beta | 0 |
| 1 Month Change | -13.33% |
| 3 Month Change | -22.06% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -63.48% |
Recent News & Updates
Shareholder Returns
| 1228 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -3.0% | 1.4% | 1.5% |
| 1Y | n/a | -51.7% | -20.8% |
Return vs Industry: Insufficient data to determine how 1228 performed against the Hong Kong Biotechs industry.
Return vs Market: Insufficient data to determine how 1228 performed against the Hong Kong Market.
Price Volatility
| 1228 volatility | |
|---|---|
| 1228 Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in HK Market | 12.8% |
| 10% least volatile stocks in HK Market | 3.2% |
Stable Share Price: 1228 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 1228's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 183 | James Qun Xue | https://www.canbridgepharma.com |
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Caphosol Mouth Rinse for temporary and persistent dryness of the mouth and throat. It also engages in the development of CAN008, an artificially engineered antibody-like fully human fusion protein for the treatment of glioblastoma multiforme; CAN108, an orally absorbed reversible inhibitor of the ileal bile acid transporter to treat rare cholestatic liver diseases; CAN106, a humanized monoclonal antibody against complement C5 being developed for the treatment of complement-mediated diseases; CAN103, a recombinant human enzyme replacement therapy (ERT); CAN104, a recombinant human ERT; CAN105, a bispecific antibody; CAN201, a gene therapy program that utilizes adeno-associated virus (AAV) sL65 capsid; and CAN202, a gene therapy program utilizing AAV sL65 capsid.
CANbridge Pharmaceuticals Inc. Fundamentals Summary
| 1228 fundamental statistics | |
|---|---|
| Market Cap | HK$1.38b |
| Earnings (TTM) | -HK$1.24b |
| Revenue (TTM) | HK$36.00m |
38.3x
P/S Ratio-1.1x
P/E RatioIs 1228 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1228 income statement (TTM) | |
|---|---|
| Revenue | CN¥31.16m |
| Cost of Revenue | CN¥12.39m |
| Gross Profit | CN¥18.78m |
| Other Expenses | CN¥1.10b |
| Earnings | -CN¥1.08b |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Aug 24, 2022
| Earnings per share (EPS) | -2.54 |
| Gross Margin | 60.25% |
| Net Profit Margin | -3,456.26% |
| Debt/Equity Ratio | 4.5% |
How did 1228 perform over the long term?
See historical performance and comparison